Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect Clinical Trial

Official title:
Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Status Completed

Clinical Trial Summary

Safety and efficacy of DE-105 ophthalmic solution in patients with persistent corneal epithelial defect will be evaluated. Dose-dependent efficacy will be evaluated as well.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Persistent Corneal Epithelial Defect

Clinical Trial Details

NCT number	NCT00988494
Study type	Interventional
Source	Santen Pharmaceutical Co., Ltd.
Contact
Status	Completed
Phase	Phase 2
Start date	September 2009

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03687632` - ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects	Phase 2
Recruiting	`NCT05966493` - A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED	Phase 2/Phase 3
Completed	`NCT05436288` - A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects	Phase 2
Recruiting	`NCT05727878` - Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED	Phase 2
Completed	`NCT02979912` - Autologous Platelet Lysate in Corneal Epithelial Defects	Phase 1/Phase 2
Terminated	`NCT05066698` - ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects	Phase 2
Withdrawn	`NCT05172349` - Use of a Biological Lens of Amniotic Membrane (LV-Visio-AMTRIX) in the Treatment of Trophic Ulcers	Phase 2